Clinical Trial Update: BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy [NA]

View source ↗

Summary

Clinical trial update for a BCMA/CD3 bispecific T-cell engager in AL amyloidosis (relapsed/refractory or newly diagnosed) noting insufficient depth of hematolog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• BCMA/CD3 bispecific T-cell engager (BCMA/CD3 bispecific T-cell engager)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: AL Amyloidosis | NA | Status: NOT_YET_RECRUITING